Morning Plenary

Todd C. Brady, M.D., Ph.D.
Entrepreneur in Residence
Domain Associates

Todd C. Brady, M.D., Ph.D. is an Entrepreneur in Residence at Domain Associates, a leading healthcare venture capital firm. He is President and Chief Executive Officer of Aldexa Therapeutics and is a member of the Board of Directors of Evoke Pharmaceuticals, Novadigm Therapeutics, ParinGenix, and Sebacia. Prior to joining Domain, Dr. Brady was co-founder and CEO of Phenome Sciences, a biotechnology firm he merged with Xanthus Pharmaceuticals (acquired by Antisoma), where he was later Executive Vice President of Strategic Development and Planning. Dr. Brady also worked as head of business development and medical director at Aderis Pharmaceuticals (acquired by Schwarz Pharma, now part of UCB). While at Xanthus and Aderis, Dr. Brady was a medical consultant on numerous pre-clinical programs and clinical programs in Phases I through IV. Earlier in his career, Dr. Brady was a senior associate at CB Health Ventures (now Excel Medical Ventures), a healthcare venture capital fund. Dr. Brady holds an M.D. from Duke University Medical School, a Ph.D. from Duke University Graduate School, and an A.B. from Dartmouth College.

Stephen K. Burley, M.D., D.Phil.
Director of the Center for Integrative Proteomics Research
Distinguished Professor of Chemistry and Chemical Biology
Member, Cancer Institute of New Jersey, Rutgers, The State University of New Jersey

Dr. Stephen K. Burley is the director of the Rutgers’ Center for Integrative Proteomics Research, the parent center for the world-renowned Research Collaboratory for Structural Bioinformatics Protein Data Bank. Dr. Burley, whose work revolves around oncology and structural biology, is an M.D. and Ph.D.,  his medical degree from the Harvard-MIT Health Sciences and Technology program and his doctoral degree in molecular biophysics from Oxford University as part of the Rhodes program.

Dr. Burley founded Prospect Genomic Inc., which was eventually acquired by Eli Lilly and Co. in 2008, where Dr. Burley has spent the previous four years as a distinguished research scholar. He has also served as a researcher and professor at Rockefeller University, where he was selected to become a Howard Hughes Medical Institute investigator.

David Kimball, Ph.D.
Research Professor
Rutgers University, School of Pharmacy
Associate Vice President for Interdisciplinary and Translational Research, Office of the Vice President of Research 

David Kimball has 30 years experience in the discovery and development of small molecule drug candidates.  He is currently Research Professor at Rutgers University in the School of Pharmacy and is Associate Vice President for Interdisciplinary and Translational Research in the Office of the Vice President of Research, where he is involved with coordinating activities as well as helping to effect the merger of Rutgers University with the UMDNJ medical schools and the Cancer Institute of New Jersey.  Before he joined Rutgers in 2011, David was Chief Scientific Officer at Hydra Biosciences, a biopharmaceutical company based in Cambridge, Massachusetts which is focused on applying its understanding of Transient Receptor Potential (TRP) ion channels to the discovery of drugs for pain, inflammation and respiratory disease.  Prior to joining Hydra in 2008, David was Senior Vice President of Research at Pharmacopeia, and was responsible for all research alliances as well as drug discovery research and non-clinical development.

Dr. Kimball spent six years at Lexicon Pharmaceuticals in Princeton, NJ as Vice President of Medicinal Chemistry beginning in 2001.  While there, David was responsible for building an organization of over 75 chemists, including medicinal, analytical, computational, process research and development, library synthesis and outsourcing chemistry.  Lexicon Pharmaceuticals’ small molecule pipeline was derived from applying this chemistry capability to the novel drug targets discovered by its genetics platform.

David spent the 19 years prior to Lexicon at Bristol-Myers Squibb Pharmaceutical Research Institute, most recently as Research Fellow in the Division of Medicinal Chemistry, Princeton, NJ.  During his tenure at BMS, he led several significant drug discovery and development research efforts that culminated in clinical compounds, including inhibitors of cyclin-dependent kinase 2, a molecular target in oncology for the treatment of solid tumors, inhibitors of the serine protease thrombin for the treatment of arterial and venous thrombosis and long-acting calcium channel blockers for the treatment of hypertension and angina.

Dr. Kimball has lectured widely on drug discovery and had been an Associate Member of the Graduate Faculty at Rutgers University School of Pharmacy since 1989.  He holds a Ph.D. in Organic Chemistry/Chemical Biology from the State University of New York at Stony Brook.  His thesis work was titled “Total Synthesis of Anthracyclinones”, with Professor Francis Johnson.

Eric T. Olson, MBA
Sanofi-Genzyme BioVentures

Eric Olson is a Director on the Sanofi-Genzyme BioVentures team and was previously a Senior Associate of Genzyme Ventures.  Prior to joining Genzyme Ventures, Eric was a Business Development Manager in Genzyme’s Corporate Development group, where he evaluated and led numerous business development opportunities spanning several therapeutics areas and stages of development. Prior to joining Genzyme, Eric was an investment banker at Benedetto, Gartland & Co., a boutique that specialized in raising private equity for select private equity sponsors and corporations.  Eric began his career as a Research Assistant at the Yale University School of Medicine, where he published several papers in peer-reviewed journals.

Eric holds an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia, an M.S. in Cellular and Molecular Biology from New York University, and a B.A. in Zoology from Connecticut College.

Gary L. Olson, Ph.D.
President and CEO
Provid Pharmaceuticals Inc.

Dr. Olson is a drug discovery entrepreneur and scientist-executive with prominent track record in pharma and biotech. He is a pioneer in the field of peptide mimetics technology and a leader in rational drug design.  Following a career path at Roche and Praecis, Dr. Olson co-founded Provid Pharmaceuticals in 2001 and is responsible for the strategic direction of the company and for leadership of multiple internal and client drug discovery programs.  Dr. Olson has extensive experience in business development, licensing and managing drug discovery programs.  Provid’s business model couples drug discovery services to generate revenue with internal projects to create value that will be monetized through licensing.

Key scientific achievements in Dr. Olson’s career include the discovery of Provid’s MHC class II inhbitors for the treatment of autoimmune disease with his Provid colleagues (e.g., PV-267 , Provid’s drug candidate for multiple sclerosis), contributions to the field of receptor modeling and the design of piquindone (antipsychotic) and TRH mimetics as cognition-enhancing drugs.  These discoveries have resulted in 60 US patents/applications and 10 funded government and foundation grants.

Dr. Olson received his Ph.D. in Chemistry from Standford University and his A.B. from Columbia University.

Andrew L. Pecora, M.D., F.A.C.P., C.P.E.
Chairman and Executive Administrative Director
John Theurer Cancer Center
Hackensack University Medical Center  

When Dr. Andrew L. Pecora joined the John Theurer Cancer Center, he elevated cancer care to the department level and reorganized cancer services into 14 separate divisions. His accomplishments include the aggressive recruitment of leading oncologists from all over the United States, the addition of innovative basic research and clinical trials, the expansion of patient care services, and the acquisition of new state-of-the-art technology that has helped make the John Theurer Cancer Center one of that nation’s top 50 best cancer centers – the only one in New Jersey with this designation.

A certified Hematologist/Oncologist, Dr. Pecora is recognized internationally as one of the world’s foremost experts in blood and marrow stem cell transplantation, cellular medicine, and immunology research. In 1989, he spearheaded the development of The John Theurer Cancer Center’s Adult Blood and Marrow Stem Cell Transplantation Program and is responsible for many advancements used in stem cell transplantation today. Dr. Pecora’s current research involves developing vaccines and other cellular medicine techniques that boost the capabilities of a patient’s own immune system to fight cancer and targeted therapies that destroy cancer cells. His research has been published extensively in prestigious medical journals and is a frequently requested lecturer at conferences all over the world. Dr. Pecora’s award-winning research is funded by the National Cancer Institute, Amgen, Merck, and the AHEPA Research Foundation.

Blaine Templeman

Partner, New York
Sheppard Mullin Richter & Hampton LLP 

Blaine Templeman is the Managing Partner of Sheppard, Mullin, Richter and Hampton LLP’s New York office and a partner in the Corporate and Intellectual Property Practice Groups (IP Transactions).  He serves as co-leader of the firm’s Life Sciences group and Technology Transactions practice group. Mr. Templeman’s practice focuses on counseling U.S. and international clients in the protection, development and commercialization of their products and IP portfolios through domestic and cross-border intellectual property transactions, precision manufacturing, contract manufacturing, clinical trials, research and outsourcing. His transactional work includes mergers and acquisitions, asset sales, collaborations, licensing transactions, manufacturing and distribution arrangements and copromotions. Mr. Templeman also works on technology transactions focusing on licensing, distribution arrangements and contract manufacturing (including OEM), as well as assets transactions, product development collaborations and joint ventures. He has worked closely with several of his clients to complete transactions in the US, EU, Russia, Israel, Lebanon, Australia, New Zealand, India, Japan, Korea, Taiwan, Brazil, Argentina, Peru, Mexico, Guatemala and many other countries.

Luncheon Plenary

Christopher P. Austin, M.D.
Director, National Center for Advancing Translational Sciences
National Institutes of Health 

Christopher Austin is Director of the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health. NCATS’ mission is to catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Before becoming NCATS Director in September 2012, he was director of the NCATS Division of Preclinical Innovation, which focuses on translating basic science discoveries into new treatments, particularly for rare and neglected diseases, and developing new technologies and paradigms to improve the efficiency of therapeutic and diagnostic development. In this role, he founded and directed numerous initiatives including the NIH Chemical Genomics Center (NCGC), the Therapeutics for Rare and Neglected Diseases (TRND) program, and the Toxicology in the 21st Century (Tox21) program. Before joining NIH in 2002, Dr. Austin directed research programs genomics-based target discovery, pharmacogenomics, and neuropsychiatric drug development at Merck, with a particular focus on schizophrenia. Dr. Austin received his A.B. in biology from Princeton and M.D. from Harvard Medical School.  He completed clinical training in internal medicine and neurology at the Massachusetts General Hospital, and a fellowship in genetics at Harvard.

Afternoon Plenary

Graham R. Brazier
Vice President, Business Development
Bristol-Myers Squibb Company 

Graham joined Bristol Myers Squibb in 2002 and has transactional responsibility for the full array of collaborations covering research, clinical and commercial stage assets across BMS’ global pharmaceutical business.  Graham is also responsible for Japan Partnering activities.

Prior to joining BMS, Graham was Senior Vice President, Corporate Development at 3-Dimensional Pharmaceuticals, a drug discovery company and before that Vice President, Worldwide Business Development at SmithKline Beecham Pharmaceuticals, where he spent 10 years.

Graham has successfully led and overseen numerous transaction teams involved in company acquisitions, co development and co promotion deals, compound in and out licensing, product disposals, research collaborations, patents licenses and other strategic transactions.

Originally from the UK, Graham has lived and worked in Holland, Belgium and the USA, where he has spent the last 18 years.

Graham is a fellow of the Chartered Association of Certified Accountants, United Kingdom.